VisiRose
Private Company
Funding information not available
Overview
VisiRose is a private, pre-revenue biotech company developing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT) for ocular infections, primarily infectious keratitis. The technology, licensed from the University of Miami's Bascom Palmer Eye Institute, uses a topical photosensitizer activated by light to destroy a wide range of pathogens without known resistance. With a seasoned management team connected to its parent company Provectus Biopharmaceuticals, VisiRose aims to address a significant global health need where current treatments are often invasive, ineffective against drug-resistant strains, or inaccessible.
Technology Platform
Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT): A photodynamic therapy using topical bioactive synthetic small molecule Rose Bengal activated by light to generate reactive oxygen species that destroy a broad spectrum of microbial pathogens (bacterial, fungal, viral, parasitic) without known resistance mechanisms.
Opportunities
Risk Factors
Competitive Landscape
Competition includes traditional and newly developed topical antimicrobials, and in severe cases, corneal transplant surgery. VisiRose's primary differentiation is RB PDAT's broad-spectrum, non-resistance mechanism and potential to serve as a non-surgical curative intervention, a niche not currently filled by approved pharmacotherapies.